Investigational drug · Phase 3
A166
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Her 2 Positive Breast Cancer, HER2-positive Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "A166"
First trial start
2023
Jul 18, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "A166", any sponsor or status.
Conditions studied
As listed on its trial records.
- Her 2 Positive Breast Cancer
- HER2-positive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "A166" as an intervention, largest first.
- A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyPivotal-lookingActive, not recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT06968585 · 365 participants · Start Jul 18, 2023 · Primary completion Nov 30, 2026
Drug: A166; T-DM1 · For: HER2-positive Breast Cancer
Sites: Shanghai, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT05311397 · 129 participants · Start Aug 1, 2018 · Primary completion Apr 9, 2026
Drug: A166 · For: Breast Cancer
Sites: Shanghai, China
Klus Pharma Inc.Industry
NCT03602079 · 49 participants · Start Jul 16, 2018 · Primary completion Jan 12, 2022
Drug: A166 · For: HER2-positive Breast Cancer; HER2 Gene Mutation; HER-2 Gene Amplification and 41 more
Sites: Sarasota, Florida; Boston, Massachusetts; Detroit, Michigan · 10 sites in all
Fudan UniversityAcademic, hospital or other
NCT05346328 · 48 participants (planned) · Start Jun 1, 2022 · Primary completion Dec 31, 2023
Drug: Injection of A166 · For: Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07299825 · 40 participants (planned) · Start Sep 20, 2024 · Primary completion Sep 20, 2027
Drug: A166 · For: Her 2 Positive Breast Cancer
Sites: Zhenzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Liu F, Pan Y, Li J, et al. · Front Pharmacol 2026
- HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).
Richani Meinhardt FW, Zambrano Iglesias MI, Fernández Gómez MP, et al. · Int J Mol Sci 2026
- Structural insights into the nirmatrelvir-resistant SARS-CoV-2 Mpro L50F/E166A/L167F triple mutant-inhibitor-complex reveal strategies for next generation coronaviral inhibitor design.
Fischer C, Lu J, van Belkum MJ, et al. · RSC Med Chem 2025
- HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.
Ismail A, Desai A, Boumber Y · Front Oncol 2025
- An Insight into the Crystal Growth of 7-Aminodeacetoxycephalosporanic Acid from the Perspective of the Growth Unit.
Hao Z, Cheng X, Han Y, et al. · J Phys Chem A 2025
- Transforming waste wood into pure L-(+)-lactic acid: Efficient use of mixed sugar media through cell-recycled continuous fermentation.
Schroedter L, Schneider R, Venus J · Bioresour Technol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.